Results of the ACCORD BP trial16: A) Efficacy outcomes and B) adverse events.
| A) | SBP TARGET, % | ||||
|---|---|---|---|---|---|
| EFFICACY OUTCOMES | < 140 mm Hg (MODERATE) | < 120 mm Hg (INTENSIVE) | ARR, % | RRR, % | NNT (95% CI) FOR 4.7 Y* |
| Primary outcome (nonfatal MI, nonfatal stroke, death from cardiovascular causes) | 10.0 | 8.8 | 1.2 | 11.9 | NS |
| Stroke | 2.6 | 1.5 | 1.1 | 41.7 | 92 (53-356) |
| Macroalbuminuria | 8.7 | 6.6 | 2.1 | 24.5 | 47 (27-179) |
| B) | SBP TARGET, % | ||||
|---|---|---|---|---|---|
| ADVERSE EVENTS | < 140 mm Hg (MODERATE) | < 120 mm Hg (INTENSIVE) | ARI, % | RRI, % | NNH (95% CI) FOR 4.7 Y |
| Total mortality | 6.1 | 6.3 | 0.2 | 4.5 | NS |
| Serious adverse events from antihypertensive medication† | 1.3 | 3.3 | 2.0 | 157.5 | 50 (35-87) |
| Potassium level < 3.2 mmol/L | 1.1 | 2.1 | 1.0 | 82.1 | 107 (61-457) |
| eGFR < 30 mL/min/1.73 m2 | 2.2 | 4.2 | 0.9 | 91.1 | 50 (33-100) |
ARI—absolute risk increase, ARR—absolute risk reduction, eGFR—estimated glomerular filtration rate, MI—myocardial infarction, NNH—number needed to harm, NNT—number needed to treat, NS—not statistically significant, RRI—relative risk increase, RRR—relative risk reduction, SBP—systolic blood pressure.
↵* NNT and 95% CI calculated with the Dalhousie University Katie Clinical Significance Calculator.17
↵† Serious adverse events are those that are life-threatening, cause permanent disability, or require hospitalization.